Appointment of Non-Executive Director

RNS Number : 8851Y

Braveheart Investment Group plc

18 May 2021

 

18 May 2021

Braveheart Investment Group plc

("Braveheart" or the "Group")

Appointment of Non-Executive Director

Braveheart Investment Group (AIM: BRH) is pleased to announce the appointment of Dr Susan (Sue) Anne Hagan as a Non-Executive Director to the Board, with effect from today. She will also be a member of the Remuneration, Audit and Compliance committees.

Dr Sue Hagan brings a wide range of experience in research, development and commercialization of medical devices, in-vitro diagnostic (IVD) medical devices, therapeutics and related healthcare products. Currently, Sue is working on a COVID-19 in-vitro diagnostic point of care device, assisting with regulatory and clinical issues. Previously, with start-up biotech Astrimmune Ltd, she was instrumental in obtaining grants leading to collaborations with the University of Sheffield and the University of Cambridge for the development of a non-invasive bladder cancer monitoring test.

Sue works with start-up biotechs, NHS spin-offs, SMEs and Big Pharma and has managed clinical studies for oncology diagnostics and medical software, alongside regulatory affairs and grant applications. This effort included one of the earliest registrations of software as medical device in the EU based on an innovative retrospective trial design. Previously, she led early phase combination drug-device projects with Pfizer and was project manager for the development of a radiopharmaceutical oncology product into a first in human trial at Aphton Biopharma, a NASDAQ listed immunotherapeutic company, where she led the Research and Development Laboratory.

Sue is a registered pharmacist with a BSc from the University of Manchester and PhD from the University of Nottingham. She is the founder and CEO of Ourami Ltd, a creative solutions provider.

Trevor Brown, CEO of Braveheart commented, "We are very pleased that Sue has agreed to join the Board of Braveheart. I am confident that Sue's experience in the development of medical devices and management of clinical studies will be an important asset to the Company."

For further information:

Braveheart Investment Group plc	Tel: [phone]
Trevor Brown CEO
Allenby Capital Limited (Nominated Adviser and Joint Broker)	Tel: [phone]
David Worlidge / James Reeve / George Payne
Peterhouse Capital Limited (Joint Broker)	Tel: [phone]
Heena Karani / Lucy Williams

Additional Information

Susan Anne Hagan (formerly Haigh), aged 51 years, is a director of Astrimmune Limited and Ourami Limited.

No further information is required to be disclosed under AIM Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

 

END

 

 

BOADZGMKFNFGMZM